209 results about "Tuberculoma" patented technology

The invention provides a compound as shown in a formula (I), a stereoisomer thereof, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a crystal form thereof, an isotope derivative thereof, a prodrug thereof and a metabolite thereof. The solvate or hydrate of the compound can be used for preparing a pharmaceutical composition for treating and / or preventing diseases related to mycobacterium tuberculosis and / or nontuberculous mycobacterium. The compound provided by the invention has an excellent bactericidal effect and strong specificity, has no cross resistance with the existing antituberculosis drugs, and provides a breakthrough direction for treatment of drug-resistant tuberculosis.

The invention discloses an electrochemical biosensor for detecting mycobacterium tuberculosis. The sensor takes a porous membrane as a base material, the inner wall of a pore channel of the porous membrane is co-modified with a polydopamine (PDA) and conductive carbon material composite layer, and an amino-modified specific capture probe based on a mycobacterium tuberculosis ESAT-6 gene is fixed on a modification layer through covalent binding. When a target gene is captured by a probe, the volume effect of the target gene causes blockage of a porous channel of the porous membrane, so that electrochemical signals (such as current) of the sensor are changed, and high-sensitivity and specific detection of mycobacterium tuberculosis is realized. According to the invention, a porous structure, biological probe specific fixation and an electrochemical signal conversion technology are combined, and a novel efficient tool is provided for rapid diagnosis of tuberculosis.

The invention discloses a method for establishing indirect ELISA (enzyme-linked immunosorbent assay) for detecting mycobacterium bovis Lprl, which comprises the following steps: preparing mycobacterium bovis Lprl protein, taking the purified protein as an antigen, and determining conditions such as optimal antigen coating concentration, serum dilution, serum incubation time, secondary antibody dilution concentration, incubation time and the like. The established indirect ELISA detection method does not have cross reaction with other bovine pathogens, the specificity is good, the detection accuracy is high, and the total coincidence rate of test results of intradermal allergy with bovine tubercle bacillus is 95.8%; the intra-batch variation coefficient of the detected samples is 2.43%-3.61%, the inter-batch variation coefficient is 2.83%-3.96%, and the intra-batch variation coefficient and the inter-batch variation coefficient are both smaller than 10%. A new diagnosis target is developed, the established indirect ELISA method has the characteristics of high sensitivity, strong specificity, good repeatability and the like, the operation is easy, and a new method is provided for the detection work of the mycobacterium bovis.

A multi-modal AI model for assisting knee joint tuberculosis diagnosis belongs to the field of assisting knee joint tuberculosis diagnosis and comprises a 3D image modal input module, a text modal input module, a test result modal input module, a multi-modal feature fusion module and a large language module. Aiming at the problems that the early diagnosis time of knee joint tuberculosis is too long and subjective interpretation is different, the diagnosis accuracy can be improved while the diagnosis time is shortened; according to the invention, an M3D model framework is optimized, CT / MRI images, laboratory indexes and text data are fused, and a multi-modal feature interaction auxiliary diagnosis system is constructed; according to the invention, accurate identification of early lesions of knee joint tuberculosis is realized, the misdiagnosis rate is reduced, and efficient and objective quantitative decision support is provided for clinic; according to the invention, the problems of high misdiagnosis rate and long flow caused by insufficient specificity in early diagnosis and examination of knee joint tuberculosis are solved through technical innovation.

This invention provides a data storage method and system for tuberculosis detection, relating to the field of tuberculosis detection technology. The data storage method for tuberculosis detection includes the following steps: S1. Collecting whole-genome sequencing data of Mycobacterium tuberculosis, host serum IgG titer, and drug sensitivity test results; S2. Calculating genetic distance D based on a reverse evolution model to generate four-dimensional spatiotemporal coordinates (t, x, y); S3. Performing data partitioning and storage based on the drug target barrier value β; S4. Generating dynamic metadata using a host-pathogen dynamics model and compressing and storing it. This invention implements a dynamic storage entropy adjustment algorithm at the hardware and software collaborative level, continuously optimizing the matching efficiency of data compression and physical storage. This results in an intelligent data hub that can perceive the evolutionary pulse of pathogens and autonomously optimize resources, providing support for clinical tuberculosis prevention and control decisions with temporal depth, spatial correlation, and risk evolution.

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

To provide methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle.SOLUTION: The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The method provided herein results in a change from the baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.SELECTED DRAWING: None

The application belongs to the technical field of biological medicine, and particularly relates to a blood Mycobacterium tuberculosis complex free nucleic acid detection kit and a detection method. The application first proposes a kit, wherein a PCR detection reagent group and a CRISPR / Cas12a detection reagent group are arranged in the kit; the PCR detection reagent group comprises a forward primer and a reverse primer which target a complex target; the sequence of the forward primer is overlapped with or complementary to the recognition region of the crRNA sequence, or the sequence of the reverse primer is overlapped with or complementary to the recognition region of the crRNA sequence.

The invention discloses a detection system and method for identifying mycobacteria and drug resistance genes of the mycobacteria based on nanopore sequencing, and relates to the field of biological medicine, the detection system comprises a specific targeted enrichment module, a nanopore sequencing module and a biological information analysis module; the specific targeted enrichment module comprises a probe combination, and the probe combination covers a mycobacterium tuberculosis complex conservative identification gene, species-specific genes of common nontuberculous mycobacteria and mycobacterium leprosy, and full-length or partial sequences of drug resistance related genes in a targeted manner; by utilizing the characteristics of nanopore length reading length and real-time sequencing and a tuberculosis specific targeted enrichment strategy, accurate identification of a mycobacterium tuberculosis complex group, synchronous typing of 42 mycobacteria, analysis of 24 drug-resistant genes, and efficient detection of structural variation and low-abundance heterogeneity drug-resistant mutation are realized, the detection period is shortened, the detection cost is reduced, and the detection efficiency is improved. And a comprehensive and reliable technical basis is provided for accurate diagnosis and treatment of mycobacterium infection.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The present invention provides a CRISPR system and a kit for detecting drug-resistant tuberculosis, which belong to the technical field of drug-resistant tuberculosis detection. The CRISPR system includes AaCas12b and sgRNA; the sgRNA includes a first sgRNA targeting the tuberculosis-specific sequence IS6110; and also includes a second and a third sgRNA targeting the drug-resistant tuberculosis rpoBS531L and / or katGS315T mutation sites. The present invention is based on the Crispr-AaCas12b system, targeting the tuberculosis-specific sequence IS6110 and the most common mutation sites of drug-resistant tuberculosis. By selecting PAM and adjusting the length of the sgRNA spacer binding region and artificially introducing base mismatches, Crispr-AaCas12b can specifically recognize drug-resistant mutation sites and does not recognize wild-type sequences; drug-resistant tuberculosis is quickly and accurately detected by fluorescence signal monitoring.

The invention relates to a method for detecting activation of specific T cells after tuberculosis infection and application of the method. Specifically, the invention provides a reagent combination for detection, and the reagent combination comprises an anti-CD4 antibody (CD4 antibody), an anti-CD154 antibody (CD154 antibody), an IFN-gamma detection antibody and a tuberculosis specific antigen. According to the method, through peripheral whole blood collection, PBMC cell separation, T cell activation (activation), activation termination (blocking), antibody labeling, membrane rupture, fixation, intracellular cytokine dyeing, flow cytometry detection and result analysis and judgment, the ratio of the expression IFN-gamma cells in the CD4 + CD154 + cells can be rapidly and accurately determined, and by combining an ROC curve and a constructed judgment standard, the content of the IFN-gamma cells in the CD4 + CD154 + cells can be determined, and the content of the IFN-gamma cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells in the CD4 + CD154 + cells can be determined. And the sample to be detected is judged to be in a positive / negative / gray region, so that whether a patient is infected by the mycobacterium tuberculosis or not can be more accurately diagnosed, especially aiming at a whole blood sample from a special crowd.

The invention relates to a mycobacterium tuberculosis EspB polyclonal antibody as well as a preparation method and application thereof. The purified EspB antibody has good detection specificity, only reacts with mycobacteria, and does not react with other common pneumonia pathogenic bacteria. The EspB polyclonal antibody specifically recognizes mycobacteria EspB, comprises mycobacterium tuberculosis and nontuberculous mycobacteria (NTM) EspB which grows slowly and rapidly, and can be used for detecting tuberculosis and NTM diseases.

The invention discloses a gene marker for diagnosing latent tuberculosis infection and application of the gene marker, and belongs to the technical field of biological medicine. According to the present invention, the latent tuberculosis infection early diagnosis marker is screened based on the peripheral blood whole genome DNA methylation map, the new target is provided for the diagnosis of latent tuberculosis infection, the diagnosis efficiency of the marker is evaluated through pyrosequencing, the corresponding detection kit and the use method are developed, and the rapid and accurate diagnosis of latent tuberculosis infection is achieved.

To provide monoclonal antibodies specific to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.SOLUTION: The present invention provides a monoclonal anti-PIM6 / LAM antibody, or an antigen-binding portion thereof, that specifically binds to an epitope present in LAM and PIM6, the epitope including at least one polymannose structure. The anti-PIM6 / LAM antibody includes CDR1 light chain variable region, CDR2 light chain variable region, CDR3 light chain variable region, CDR1 heavy chain variable region, CDR2 heavy chain variable region, and CDR3 heavy chain variable region, each including a specific amino acid sequence.SELECTED DRAWING: Figure 1

The invention relates to a spinal infection and tuberculosis intelligent diagnosis method based on an image large model, the core idea of the method is pre-training of a base and hierarchical fine tuning, that is, firstly, a general spinal image visual large model is trained based on a DINOv2 algorithm by using mass unmarked spinal MRI data, so that the spinal image visual large model masters the anatomical structure and basic pathological characteristics of the spinal column; and then a two-stage cascaded diagnosis network is designed on the base, so that the problems of whether infection exists or not and the infection type are solved respectively. The problems that in spinal infection differential diagnosis, labeling data is deficient and the feature extraction capacity is insufficient are solved, a DINOv2 self-supervised pre-training technology is utilized to construct a visual feature base model, automatic screening of spinal infectious diseases and accurate differential diagnosis of infection subtypes are achieved through a hierarchical two-stage reasoning architecture, and the accuracy of the spinal infection differential diagnosis is improved. Dependence on annotation data is greatly reduced, and identification accuracy of difficult cases is remarkably improved.

The invention discloses a nanometer antibody of mycobacterium tuberculosis early secretory protein ESAT-6 and application thereof, relates to the technical field of antibody recombination and genetic engineering antibodies, and is characterized by providing two nanometer antibodies AEN1 and AEN5 which are derived from a total synthesis alpaca nanometer antibody yeast display library and are combined with ESAT-6 in high affinity, DNA sequences for coding the AEN1 and the AEN5, a carrier containing the DNA, a carrier containing the carrier containing the DNA, and a carrier containing the carrier containing the carrier containing the DNA. The invention relates to a vector, a host cell containing the vector, and a method for preparing AEN1 and AEN5 by utilizing genetic engineering. And the method for quantitatively detecting the ESAT-6 by using the double-antibody sandwich ELISA is established. Detection on clinical specimens of tuberculosis shows that the sensitivity of the diagnosis method is 94.9%, and the specificity is 100%. The antibody is used for preparing gold-labeled rapid test paper, and the ESAT-6 can be rapidly detected from serum of a mycobacterium tuberculosis infected patient.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting mycobacterium tuberculosis MPT83 as well as a preparation method and application of the protective monoclonal antibody. The antibody or an antigen binding fragment comprises a CDR sequence selected from at least one of the following sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 5-7; cDR sequences of a light chain variable region are as follows: SEQ ID NO: 9-10 and LAS. The monoclonal antibody 9C9 can be specifically combined with MPT83 protein on the surface of Mycobacterium tuberculosis (MTB) and shows efficient antituberculous activity in vivo and in vitro, the activity mainly comprises the aspects of remarkably enhancing the phagocytosis of macrophages on tubercle bacillus, inhibiting tubercle bacillus growth and the like, and in addition, the monoclonal antibody 9C9 is clear in sequence and structure, easy to develop and modify and capable of being used for preparing the anti-tubercle bacillus monoclonal antibody 9C9. The monoclonal antibody 9C9 disclosed by the invention has the advantages that the monoclonal antibody 9C9 can be used for preventing and treating tuberculosis, an immune-mediated treatment mechanism of the monoclonal antibody 9C9 does not easily induce pathogens to generate drug resistance, a new choice is provided for the treatment of tuberculosis when the monoclonal antibody 9C9 is applied to prevention and treatment of tuberculosis, an important technical basis is also provided for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and the application prospect is wide.

The application discloses a kind of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image classification method, mainly including the following steps: image feature map is extracted by encoder and image feature map is divided into multiple examples, each example represents the feature information in certain area of image;The correlation weight of example and classification task is calculated, and the example is aggregated into bag feature representation according to the weight to express the characteristics of CT image;Bag feature representation is predicted as CT image category by classifier;According to the correlation weight, important examples are selected, and are evaluated by classifier, to express the correlation degree of the learning content and expected content of network;Loss function is constructed, including bag classification loss and correlation loss, respectively representing the difference between CT predicted value and true value and the difference between model learning content and expected content.The method can realize the binary classification of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis CT image, and is superior to the classification accuracy of existing method.

The present invention is directed to a vaccine composition against a disease caused by Mycobacterium tuberculosis, said composition comprising at least four nucleic acids selected from the following groups: a. a nucleic acid encoding an Ag85A, Ag85B, or Ag85C antigen; b. a nucleic acid encoding a resuscitation promoting factor (Rpf) selected from the group consisting of: RpfA, RpfB, RpfC, RpfD and RpfE; c. a nucleic acid encoding a PE / PPE antigen selected from the group consisting of: PE5, PE13, PE15, PE29, PE31, PPE1, PPE2, PPE18, PPE20, and PPE68; d. a nucleic acid encoding a disease-reactivation-related antigen selected from the group consisting of: Rv1234 / MMAR_4207, and Rv0359 / MMAR_0678, wherein said vaccine composition comprises at least one nucleic acid from each of group a, b, and c; and wherein the nucleic acids are provided on one or more nucleic acids constructs.

This invention provides a chemotherapy catheter for spinal tuberculosis, comprising a catheter with a drug channel, a flexible tube at the front end of the catheter with multiple through holes communicating with the drug channel, and a built-in one-way structure. The one-way structure includes an elastic rubber sheet at one end fixed to the inner wall of the drug channel; multiple elastic rubber sheets are stacked together in a conical shape; and a connector is connected to the rear end of the catheter, with a drug injection end for injecting medication. This invention, by inserting the catheter into the patient's body, injects medication through the drug injection end, which then passes through the drug channel and the one-way structure to prevent backflow, and finally flows out through the multiple through holes, thereby widely dispersing the medication and improving drug utilization.

The application provides a primer probe set and a kit for detecting a rifampicin-resistant gene of Mycobacterium tuberculosis, and belongs to the technical field of molecular biology detection.The primer probe set comprises RAA primers and qPCR primers targeting the rpoB gene, probe primers targeting the wild-type rpoB gene, and probe primers targeting the mutant rpoB gene.The application adopts the detection methods of RT-RAA and qPCR in sequence, and the above specific primer probe set can be combined to simultaneously and rapidly detect the 516, 526, 531 and 533 sites of the rpoB gene of Mycobacterium tuberculosis, has good specificity, and the detection sensitivity can reach 5 copies / ul, is 20 times higher than the sensitivity of qPCR (100 copies / ul), and has a 5% detection capability for heterogenic drug resistance mutation; the detection method can also greatly shorten the detection time.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting Mycobacterium tuberculosis PspA and a preparation method and application thereof, the protective monoclonal antibody comprises at least one of the following CDR sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 4-6; the light chain variable region CDR sequences are as shown in SEQ ID NO: 8-9 and WAS. The antibody or the antigen binding fragment can specifically bind to PspA protein of mycobacterium tuberculosis (MTB), shows efficient antituberculous activity in vivo and in vitro, specifically, can significantly enhance phagocytosis of macrophages on tubercle bacillus, inhibit tubercle bacillus growth and the like, and is clear in sequence and structure, so that the antibody or the antigen binding fragment is easy to develop and transform, and has broad application prospects. And moreover, an immune-mediated treatment mechanism is not easy to induce pathogens to generate drug resistance, so that when being applied to prevention and treatment of tuberculosis, not only is a new choice provided for treatment of tuberculosis, but also an important basis is provided for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and the application prospect is wide.

The application discloses a kind of absolute quantitative detection method of child respiratory tract multi-pathogen based on multi-target ladder microarray and exogenous internal reference correction.The method sets up independent micro-reaction unit to different pathogen, adds fixed amount of exogenous internal reference nucleic acid, and calculates template number by positive unit proportion combined with Poisson distribution model, then corrects the result by using the theoretical addition amount of exogenous internal reference, so as to realize parallel detection and absolute quantification of pathogen such as bocavirus, adenovirus, mycobacterium tuberculosis and mycoplasma pneumoniae without standard curve and special digital PCR equipment.The application has the advantages of high sensitivity, strong anti-interference ability, suitable for mixed infection sample analysis and clinical application, etc.

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

The invention discloses a tuberculosis infection T cell spot test method based on sample preservation time and MBS method PBMCs enrichment times, and belongs to the technical field of tuberculosis infection detection. The PBMCs are automatically enriched in a fresh whole blood sample (0-4 hours) by adopting an MBS method, a magnetic bead enrichment procedure is selected twice, a T-SPOT.TB test result is highly consistent with a result of a conventional DGC method and a magnetic bead enrichment procedure for four times, and the manual operation time is shorter; the MBS method is adopted to automatically enrich PBMCs for a long-time preserved whole blood sample (longer than 4 h), four magnetic bead enrichment procedures are selected, and the T-SPOT. TB test result is highly consistent with the result of a conventional DGC method and is remarkably superior to that of two times of MBS enrichment. Therefore, different magnetic bead enrichment procedures are adopted for fresh whole blood specimens with different preservation times, so that the detection efficiency can be effectively improved on the basis of ensuring the reliable result, the automation of T-SPOT. TB test can be realized, the manual operation time is shortened, and the detection efficiency is improved. And a more optimized pretreatment scheme and a reliable test result are provided for the T-SPOT.TB test blood sample which is stored for a long time.

The present invention relates to a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for use in the treatment of cancer.

The application provides an abdominal tuberculosis image processing method, relates to the technical field of image processing and medical image analysis, and specifically comprises the following steps: collecting abdominal tuberculosis images and making a data set, image preprocessing, a multi-scale convolution module, a multi-scale pooling module, an optimized feature fusion module, a classification prediction module, constructing an abdominal tuberculosis image processing model, and training and detecting the abdominal tuberculosis image processing model. The method pre-processes image data sets by introducing an adaptive enhancement mechanism and a noise suppression strategy, designs a multi-scale convolution module and a pooling module to realize multi-scale feature extraction and fusion, adopts low-frequency high-frequency information fusion and an adaptive weighting mechanism to optimize image feature processing, and multiple modules work together, so that the processing efficiency and classification accuracy of the abdominal tuberculosis image are significantly improved, and the method exhibits strong robustness and adaptability in image analysis of different tuberculosis lesion stages.

In one aspect, the disclosure relates to compounds effective in the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis as well as drug-sensitive tuberculosis, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating bacterial infections caused by Mycobacterium tuberculosis using the same. In an aspect, the compounds and pharmaceutical compositions are not cytotoxic. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.